Is Akari Therapeutics, Plc (AKTX) a Buy, Sell, or Hold?
NASDAQ : AKTX
Akari Therapeutics, Plc
$9 USD
-$0.3 (-3.23%)
- Volume
- 11.22K
- Average Volume
- 794.36K
- Market Capitalization
- $10.3M
- P/E Ratio
- -0.01
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $49.60
- Year Low
- $3.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.27
Company Overview
NASDAQ
Abizer Gaslightwala
Biotechnology
Healthcare
AKTX
6
US
USD
Liquidity Metrics
0.05
0.27
0.27
0.21
0.00
Sales & Valuation
-$
0.00
0.01
-0.95
-517.31
Profitability
-$20800
-$17.3M
0.00%
0.00%
-123.29%
-82.76%
P/E Metrics
-0.01
0.00
0.00
Analyst Price Target & Rating
$30.00
$30.00
$30.00
3/5
8 Analysts
-70.00%
Financial Health Scores
-14.35
2/9
-$9.83M
$33.89M
$19.51M
-$28.96M
Key Metrics (TTM)
$8.61M
0.00
-0.30
0.27
-123.29%
-130.49%
-14334.16%
-102.25%
0 days
Company Executives
| Name | Title |
|---|---|
| Abizer Gaslightwala | Chief Executive Officer, President & Director |
| Kameel D. Farag | Interim Chief Financial Officer |
| Satyajit Mitra | Executive Director & Head of Oncology |
Poll Results
No votes yet today — be the first to share your view!
About Akari Therapeutics, Plc (NASDAQ:AKTX) Stock
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics ... , Plc is headquartered in Tampa, Florida.
2026-07-22 08:40:00
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
2026-07-21 07:05:00
TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments.
2026-07-07 08:55:00
Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O.
2026-06-29 08:45:00
Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points
2026-06-04 09:30:00
Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential
2026-05-28 09:17:00
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor “What This Means” interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Why Akari Therapeutics Stock Is Falling On Tuesday?
2026-05-26 07:41:33
Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.
Akari Therapeutics Stock Jumps On Promising Preclinical Data
2026-05-22 11:17:50
Akari Therapeutics Plc (NASDAQ:AKTX) shares are ripping higher after the company released preclinical data showing AKTX‑101 produced synergistic activity alongside KRAS inhibition in KRAS-mutated pancreatic cancer models.
Frequently Asked Questions
-
What is the current Akari Therapeutics, Plc (AKTX) stock price?
-
Akari Therapeutics, Plc(NASDAQ:AKTX) stock price is $9 in the last trading session. During the trading session, AKTX stock reached the peak price of $49.6 while $3.015 was the lowest point it dropped to. The percentage change in AKTX stock occurred in the recent session was --3.23% while the dollar amount for the price change in AKTX stock was -$0.3.
-
AKTX's industry and sector of operation?
-
The NASDAQ listed AKTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AKTX?
-
Abizer Gaslightwala | Chief Executive Officer, President & Director
Kameel D. Farag | Interim Chief Financial Officer
Satyajit Mitra | Executive Director & Head of Oncology
|
| -
How many employees does AKTX have?
-
Number of AKTX employees currently stands at 6. AKTX operates from 401 East Jackson Street, Tampa, FL 33602, US.
-
Link for AKTX official website?
-
Official Website of AKTX is: https://www.akaritx.com
-
How do I contact AKTX?
-
AKTX could be contacted at phone #44 20 8004 0270 and can also be accessed through its website. AKTX operates from 401 East Jackson Street, Tampa, FL 33602, US.
-
How many shares of AKTX are traded daily?
-
The average number of AKTX shares traded daily for last 3 months was 794.36K.
-
What is the market cap of AKTX currently?
-
The market value of AKTX currently stands at $10.3M with its latest stock price at $9